Mazdutide Beats Dulaglutide for Blood Sugar and Weight Loss in Phase III Chinese Diabetes Trial

Phase III, randomized, active-controlled clinical trial conducted in China. 731 adults with type 2 diabetes on background oral anti-diabetic drugs were randomized 1:1:1 to once-weekly subcutaneous 4 mg mazdutide, 6 mg mazdutide, or 1.5 mg dulaglutide for 28 weeks. The primary endpoint was mean change in HbA1c from baseline, with a non-inferiority margin of 0.3% and subsequent superiority testing. Secondary endpoints included body weight change. Safety was assessed throughout.

The GLP-1 market is dominated by Western pharmaceutical companies (Novo Nordisk's semaglutide, Eli Lilly's tirzepatide). Mazdutide, developed by the Chinese biotech company Innovent Biologics, represents a major Chinese entry into this space. Its dual GLP-1/glucagon mechanism is distinct from tirzepatide's dual GLP-1/GIP approach, offering potentially different clinical benefits. Publication in Nature — reserved for the most significant scientific findings — signals that the global scientific community views mazdutide as a serious advance.

Mazdutide represents the glucagon-inclusion strategy: adding glucagon receptor activation to GLP-1 effects. While tirzepatide (Mounjaro/Zepbound) combines GLP-1 with GIP, mazdutide combines GLP-1 with glucagon — which increases energy expenditure and fat burning. This different mechanism could produce different clinical profiles, potentially including more fat-specific weight loss and liver disease benefits (glucagon promotes hepatic fat oxidation). The strong Chinese clinical development program, with 731 patients and a Nature publication, positions mazdutide for global regulatory submissions.

The 28-week duration is relatively short for a chronic disease treatment. The study was conducted exclusively in Chinese adults, and results may differ in other populations due to genetic and metabolic differences. The comparator was dulaglutide 1.5 mg, which is not the most potent GLP-1 drug available (semaglutide and tirzepatide are more effective). Higher GI adverse events with mazdutide may limit tolerability in some patients. Long-term cardiovascular and safety outcomes were not assessed.